MedTrace Logo

Treatment of Critically Ill Patients With Covid-19 With Convalescent Plasma

NCT04468009 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 134

Last updated 2021-08-25

No results posted yet for this study

Summary

This study aims to collect convalescent plasma and use it as experimental treatment in critically ill Covid-19 patients in order to reduce mortality and length of stay in intensive care unit.

Conditions

  • SARS-Associated Coronavirus
  • Covid19
  • SARS-CoV Infection

Interventions

BIOLOGICAL

Convalescent plasma

Convalescent plasma from patients recovering from Covid-19 and which had anti-SARS-Cov-2 antibodies

Sponsors & Collaborators

  • Hospital de Infecciosas Francisco Javier Muniz

    lead OTHER_GOV

Principal Investigators

  • Carlos A Gonzalez, MD · Hospital de Infecciosas Francisco Javier Muniz

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Max Age
100 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2020-06-25
Primary Completion
2021-01-19
Completion
2021-06-19

Countries

  • Argentina

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04468009 on ClinicalTrials.gov